CLINICAL TRIALS PROFILE FOR CYTALUX
✉ Email this page to a colleague
All Clinical Trials for CYTALUX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT06235125 ↗ | Safety and Feasibility of Intraoperative Visualization With Cytalux in Children | RECRUITING | On Target Laboratories, LLC | PHASE1 | 2024-04-08 | Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach. |
| NCT06235125 ↗ | Safety and Feasibility of Intraoperative Visualization With Cytalux in Children | RECRUITING | Ann & Robert H Lurie Children's Hospital of Chicago | PHASE1 | 2024-04-08 | Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach. |
| NCT06434909 ↗ | CYTALUX™for the Intraoperative Imaging of Prostate Cancer | RECRUITING | On Target Laboratories, LLC | PHASE1 | 2024-09-19 | This study is being done to compare how much using Cytalux™ (pafolacianine) with NIR (Near InfraRed) fluorescent imaging improves the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in ovarian cancer (2021) and lung cancer surgery (2022.) |
| NCT06434909 ↗ | CYTALUX™for the Intraoperative Imaging of Prostate Cancer | RECRUITING | Indiana University | PHASE1 | 2024-09-19 | This study is being done to compare how much using Cytalux™ (pafolacianine) with NIR (Near InfraRed) fluorescent imaging improves the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in ovarian cancer (2021) and lung cancer surgery (2022.) |
| NCT06511037 ↗ | PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis | RECRUITING | On Target Laboratories | EARLY_PHASE1 | 2024-11-13 | This is a pilot, single-arm, open label study to evaluate the ability of CYTALUX™ (pafolacianine) to help identify cancerous lesions in subjects with gastrointestinal cancers and peritoneal carcinomatosis during cytoreductive surgery. |
| NCT06511037 ↗ | PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis | RECRUITING | University of California, Irvine | EARLY_PHASE1 | 2024-11-13 | This is a pilot, single-arm, open label study to evaluate the ability of CYTALUX™ (pafolacianine) to help identify cancerous lesions in subjects with gastrointestinal cancers and peritoneal carcinomatosis during cytoreductive surgery. |
| NCT07039526 ↗ | Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer. | RECRUITING | On Target Laboratories, LLC | PHASE2 | 2025-08-19 | The goal of clinical trial is to test an FDA approved drug called Pafolacianine that attaches to cancer cells and lights up when seen through a special camera system in adults with a suspected primary diagnosis, or a high clinical suspicion of gastrointestinal, fore gut, pancreatic, hepatobiliary, esophageal malignancies and gyn malignancies planned for HIPEC/debulking, warranting surgery. The main question it aims to answer is: Can CYTALUX (pafolacianine) injection used with near-infrared (NIR) fluorescent imaging improve the detection of malignant tissue in subjects undergoing surgical resection for cancer? Participants taking part in this study will receive the study medication. Then, during the surgery the investigator team will turn on the camera to evaluate if the tumor is visible with the help of the study medication. Taking part in this study will last about 2 months. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CYTALUX
Condition Name
Clinical Trial Locations for CYTALUX
Trials by Country
Clinical Trial Progress for CYTALUX
Clinical Trial Phase
Clinical Trial Sponsors for CYTALUX
Sponsor Name
